tirzepatide surmount 3 Clinical trials of subcutaneous (SURMOUNT-1, -2 and -3 Tirzepatide after intensive lifestyle intervention

Capsules may contain less than 1% magnesium stearate, an inert ingredient used in the encapsulation process

Conflict of interest The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as potential conflicts of interest

A history of pancreatitis Pancreatitis (inflammation of the pancreas) has been reported in people on GLP-1 medications, though its uncommon and the absolute risk increase is small

It hydrates, soothes, and illuminates the skin

For example, the injectable version of tirzepatide took about five years from early research to FDA approval in 2022